Stone X Group Inc. Otonomy, Inc. Transaction History

Stone X Group Inc.

  • $2.29 Trillion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Aug 13, 2025
BUY
$0.25 - $2.24 $3,180 - $28,499
12,723 New
12,723 $3.75 Million

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email